-
Mathematical Biosciences and Engineering, 2019, 16(6): 7375-7383. doi: 10.3934/mbe.2019368.
Research article
-
Export file:
Format
- RIS(for EndNote,Reference Manager,ProCite)
- BibTex
- Text
Content
- Citation Only
- Citation and Abstract
High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma
Department of Oncology,The Second Hospital of Nanjing, Nanjing University of Chinese Medicine,Nanjing, Jiangsu,210003,China
Received: , Accepted: , Published:
Keywords: agrin; hepatocellular carcinoma; progression; prognosis
Citation: Qi-Jia Zhang, Li Wan, Han-Feng Xu. High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Mathematical Biosciences and Engineering, 2019, 16(6): 7375-7383. doi: 10.3934/mbe.2019368
References:
- 1. F. Bray, J. Ferlay, I. Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA-Cancer J. Clin., 68 (2018), 394–424.
- 2. S. F. Altekruse, K. A. McGlynn, L. A. Dickie, et al., Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008, Hepatology, 55 (2012), 476–482.
- 3. S. Whittaker, R. Marais and A. X. Zhu, The role of signaling pathways in the development and treatment of hepatocellular carcinoma, Oncogene, 36 (2010), 4989–5005.
- 4. H. Huynh, R. W. Ong, P. Y. Li, et al ., Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma, Anticancer Agents Med. Chem., 11 (2011), 560–575.
- 5. P. Kischel, F. Guillonneau, B. Dumont, et al ., Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells, Neoplasia, 10 (2018), 1014–1020.
- 6. P. Tátrai, A. Somorácz, E. Batmunkh, et al ., Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions, Am. J. Surg. Pathol., 33 (2009), 874–885.
- 7. P. Tatrai, J. Dudas, E. Batmunkh, et al ., Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma, Lab Invest., 86 (2006), 1149–1160.
- 8. U. Winzen, G. J. Cole and W. Halfter, Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters, J. Biol. Chem., 278 (2003), 30106–30114.
- 9. G. Bezakova and M. A. Ruegg, New insights into the roles of agrin, Nat. Rev. Mol. Cell Biol., 4 (2003), 295–308.
- 10. A. Somorácz, P. Tátrai, G. Horváth, et al., Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas, Hum. Pathol., 41 (2010), 1310–1319.
- 11. M. Gautam, P. G. Noakes, L. Moscoso, et al., Defective neuromuscular synaptogenesis in agrin-deficient mutant mice, Cell, 85 (1996), 525.
- 12. E. Batmunkh, P. Tátrai, E. Szabó, et al., Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma, Hum. Pathol., 38 (2007), 1508–1515.
- 13. L. C. van Kempen , D. J. Ruiter , G. N. van Muijen, et al., The tumor microenvironment: a critical determinant of neoplastic evolution, Eur. J. Cell Biol., 82 (2004), 539–548.
- 14. A. Naba, K. R. Clauser, S. Hoersch, et al., The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices, Mol. Cell Proteom., 11 (2012): M111.014647.
- 15. U. Barash, V. Cohen-Kaplan, I. Dowek, et al., Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis, FEBS J., 277 (2010), 3890–3903.
- 16. A. D. Theocharis, S. S. kandalis, G. N. Tzanakakis, et al., Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting, FEBS J., 277 (2010), 3904–3923.
- 17. R. V. Iozzo and R. D. Sanderson, Proteoglycans in cancer biology, tumour microenvironment and angiogenesis, J. Cell Mol. Med., 15 (2011), 1013–1031.
- 18. I. J. Edwards, Proteoglycans in prostate cancer, Nat. Rev. Urol., 9 (2012), 196–206.
- 19. C. Mundhenke, K. Meyer, S. Drew, et al., Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas, Am. J. Pathol., 160 (2002): 185–194.
Reader Comments
© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)
Associated material
Metrics
Other articles by authors
Related pages
Tools
your name: * your email: *